Editorial: Expert opinions and perspectives in adoptive cell therapy for cancer: 2022.
作者信息
Martín-Antonio Beatriz
机构信息
Department of Experimental Hematology, Instituto de Investigación Sanitaria-Fundación Jiménez Diaz (IIS-FJD), University Autonomous of Madrid (UAM), Madrid, Spain.
出版信息
Front Immunol. 2023 Jul 20;14:1257016. doi: 10.3389/fimmu.2023.1257016. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Expert opinions and perspectives in adoptive cell therapy for cancer: 2022.社论：2022年癌症过继性细胞治疗的专家意见与观点
Front Immunol. 2023 Jul 20;14:1257016. doi: 10.3389/fimmu.2023.1257016. eCollection 2023.
2
Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.嵌合抗原受体 T 细胞疗法治疗癌症：以基础研究为导向的观点。
Immunotherapy. 2018 Mar;10(3):221-234. doi: 10.2217/imt-2017-0133.
3
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.实体瘤过继细胞免疫治疗：除 CAR-T 以外的方法
Mol Cancer. 2023 Feb 7;22(1):28. doi: 10.1186/s12943-023-01735-9.
4
Chimeric Antigen Receptor (CAR) T-cell Therapy: A New Genetically Engineered Method of Immunotherapy for Cancer.嵌合抗原受体（CAR）T细胞疗法：一种新型的癌症基因工程免疫疗法。
Curr Cancer Drug Targets. 2023;23(3):199-210. doi: 10.2174/1568009622666220928141727.
5
Making CAR T Cells a Solid Option for Solid Tumors.将 CAR T 细胞疗法变为实体瘤的可靠选择。
Front Immunol. 2018 Nov 8;9:2593. doi: 10.3389/fimmu.2018.02593. eCollection 2018.
6
In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.体外转录信使 RNA 嵌合抗原受体 T 细胞（IVT mRNA CAR T）疗法在血液系统恶性肿瘤和实体瘤治疗中的临床前进展。
Int J Mol Sci. 2020 Sep 6;21(18):6514. doi: 10.3390/ijms21186514.
7
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.工程化 CAR-巨噬细胞作为实体瘤的过继免疫疗法。
Front Immunol. 2021 Nov 24;12:783305. doi: 10.3389/fimmu.2021.783305. eCollection 2021.
8
Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.嵌合抗原受体修饰 T 细胞及其在实体瘤免疫治疗中的应用。
Expert Rev Mol Med. 2022 Jan 28;24:e7. doi: 10.1017/erm.2021.32.
9
Applications of single-cell omics for chimeric antigen receptor T cell therapy.单细胞组学在嵌合抗原受体 T 细胞治疗中的应用。
Immunology. 2024 Mar;171(3):339-364. doi: 10.1111/imm.13720. Epub 2023 Nov 27.
10
The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.嵌合抗原受体 T 细胞疗法在乳腺癌中的研究现状：前景与展望。
Front Immunol. 2022 Jul 22;13:887471. doi: 10.3389/fimmu.2022.887471. eCollection 2022.
本文引用的文献
1
FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma.FDA 批准概要：Axicabtagene Ciloleucel 二线治疗大 B 细胞淋巴瘤。
Clin Cancer Res. 2023 Nov 1;29(21):4331-4337. doi: 10.1158/1078-0432.CCR-23-0568.
2
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.阿基仑赛治疗大 B 细胞淋巴瘤的总生存。
N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5.
3
CAR-T: What Is Next?嵌合抗原受体T细胞疗法：接下来会怎样？
Cancers (Basel). 2023 Jan 21;15(3):663. doi: 10.3390/cancers15030663.
4
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus.靶向CD19的嵌合抗原受体T细胞治疗难治性系统性红斑狼疮
N Engl J Med. 2021 Aug 5;385(6):567-569. doi: 10.1056/NEJMc2107725.
Zotero 插件